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Karen J. Goodman, Ph.D.,1 Linda T. Titus-Ernstoff, Ph.D.,4 Elizabeth E. Hatch, Ph.D.,5 Arthur L. Herbst, M.D.,6
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Abstract
Purpose: To determine if women exposed in utero to diethylstilbestrol (DES) are more likely than unexposed
women to receive recommended or additional breast cancer screening examinations.
Methods: 1994 Diethylstilbestrol-Adenosis (DESAD) cohort data are used to assess the degree of recommended
compliance of breast cancer screenings found in 3140 DES-exposed and 826 unexposed women. Participants
were enrolled at four sites: Houston, Boston, Rochester, and Los Angeles. Logistic regression modeling was used
to analyze mailed questionnaire data that included reported frequency over the preceding 5 years (1990–1994) of
breast-self examinations (BSEs), clinical breast examinations (CBEs), and mammograms.
Results: DES-exposed women exceeded annual recommendations for CBEs (aOR 2.20, 95% CI, 1.04-4.67) among
women without a history of benign breast disease (BBD) compared with unexposed women. There were no
other statistically significant differences between exposed and unexposed women who reported performing
BSEs, CBEs (<40 years of age), and mammographies, regardless of BBD history.
Conclusions: The majority of DES-exposed women receive breast cancer screenings at least at recommended
intervals, but over two thirds do not perform monthly BSEs. Future efforts should be focused on further
educating this and other at-risk populations through mailed reminders and during patient consultations on the
benefits of screening examinations.
Introduction
Diethylstilbestrol (DES), a nonsteroidal estrogen firstsynthesized in 1938, was given to women to prevent
miscarriages by increasing their progesterone hormone le-
vels.1,2 In 1971, it was found to cause a rare vaginal adeno-
carcinoma, seen in young women born in the New England
area.3 That same year, the Federal Drug Administration
(FDA) halted its use during pregnancy.4 Subsequently, the
Diethylstilbestrol-Adenosis (DESAD) project was formed to
examine the scope of the public health issue and to help
provide recommendations. It has been estimated that a total
of 267 pharmaceuticals companies manufactured DES in the
United States during the period of its use, and estimates of the
number of white, middle-class women prescribed DES while
pregnant during the years 1957–1971 (the peak years of use) are
in the range of 2–10 million.2,5 The project originally comprised
four centers: Baylor College of Medicine, Houston, Texas;
Massachusetts General Hospital, Boston, Massachusetts; the
Mayo Clinic, Rochester, Minnesota; and the University of
Southern California, Los Angeles, California.6 The purpose of
this DESAD project was to follow the exposed population
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through a prospective study.6 The councils of the American
College of Obstetrics and Gynecologists (ACOG), along with
the National Institutes of Health (NIH), recommended con-
tinued follow-up of this in utero-exposed group.7
Several studies have examined the risk of breast cancer in
women who were either exposed in utero to DES or prescribed
the drug while pregnant.8–13 In a 2002 study by Palmer et al;8
DES-exposed daughters>age 40 were found to have a 2.5 fold
increased risk for breast cancer. Similarly, in a later study,
DES-exposed women >age 40 were discovered to have an
almost 2-fold increased risk for breast cancer, and women
>age 50 were estimated to have a 3-fold increased risk.13 A
slight risk for breast cancer in mothers who ingested DES
orally has been seen in other studies.9–12 In light of this
possible increased risk, this current study examines whether
women exposed in utero to DES are more likely to receive
recommended or additional breast cancer screening ex-
aminations compared with unexposed women.
Materials and Methods
Patient recruitment, including follow-up information for
this cohort has been described.3,4,14 Briefly, DES-exposed
women were recruited through information gathered through
record review, physician referral, or walk-ins through four
main centers located throughout the United Sates. These
locations included rural as well as urban populations located
at the center sites, Boston, Rochester, Houston, and Los An-
geles. The unexposed women were recruited from informa-
tion available in prenatal medical records during that time.
Siblings of the exposed women, along with women recruited
through record review, were matched on exposed women’s
age within 6 months and on her mother’s age during preg-
nancy within 5 years. At the start of 1975 through 1983, both
exposed and unexposed participants were examined an-
nually. They were then followed with a yearly questionnaire
from 1984 to 1989.6,15 Again in 1994, self-administered ques-
tionnaires were mailed to previous DESAD participants.15
This study has been reviewed and approved by Institutional
Review Boards at each participating study site.
Recommendation definitions
Information describing breast cancer screening behaviors
was obtained from the 1994 questionnaire, which included the
number of clinical breast examinations (CBEs) and mammo-
grams and the frequency of breast self-examinations (BSEs).
The time period of the self-reported screening behavior was
between 1990 and 1994. Because the data were not verified
through chart review, the results are the women’s perceptions
of their behavior. Screening is divided by a previous diagnosis
of benign breast disease (BBD) to determine if any behavior
differences exist between the two populations with a previous
breast diagnosis. Frequency was divided into a compliant
group and exceeded recommendation group to further study
the behavior differences of the exposed and unexposed po-
pulations.
During the study period, there were no specific breast
cancer screening recommendations for in utero DES-exposed
women.16,17 Therefore, the recommendations for the un-
exposed population were applied to all women in this study.
In the 5 years prior to 1994, the Council on Scientific Affairs
along with the American Cancer Society recommended a
monthly BSE for all women >age 20 and a CBE every 3 years
in women aged 20–39 and annually for women aged 40.
Furthermore it was suggested that women aged 40–49 receive
a mammogram every 1 or 2 years and annually for women
>age 50.18,19
Compliance for BSE was defined for all age groups as oc-
curring once a month or more, and noncompliance was de-
fined as every 2–3 months or less often. For CBE, compliance
for women aged 20–39 was defined as once in the past 5 years,
and exceeding recommendations was defined as two to three
times or more, with none in the past 5 years as the reference
group. Additionally, compliance for CBEs in women aged
40–49 was defined as four or five CBEs, and exceeding re-
commendations was defined as more than five CBEs in the
same time frame. Both of these groups were compared with
women reporting fewer than four CBEs. Similarly, for mam-
mography, compliance for women aged 40–49 was defined as
having had a mammogram two or three times in the past 5
years, and exceeding recommendations was defined as four
or more mammograms. After 5 years was subtracted from the
women’s ages at the time of the survey (to place women in
their appropriate recommendation by age for mammography
and CBEs), no exposed or unexposed women in the study
group were >age 49.
Data analysis
The analysis addressed the association between DES ex-
posure and reported frequency of breast cancer screenings.
Analysis showing patterns of breast cancer screening (BSEs,
mammography, and CBEs) in relation to DES exposure was
evaluated by strata of BBD, as a slightly increased risk for breast
cancer had been found in DES-exposed mothers.9–12 A family
history of any cancer was also analyzed to determine any dif-
ference between the two groups. All statistical evaluation was
performed using SPSS 11.0 statistical software (SPSS, Inc.,
Chicago, IL.) and EpiInfo 6.04d (Geneva, Switzerland).
Although the parent study used a prospective cohort de-
sign, adjusted odds ratios (aOR) were chosen as the relevant
measure of association between DES exposure status and
screening frequency in the past 5 years to control for multiple
variables through logistic regression. Three of the four de-
pendent outcome variables had three frequency levels (BSEs
had only two levels). Separate binary (i.e., compliant vs.
noncompliant and exceeding recommendations vs. non-
compliant) logistic regression models were used to estimate
the ORs and 95% confidence intervals (CI) for each of the two
outcome categories that met or exceeded recommendations
compared with the reference category.20
Potential confounders for exposure-outcome associations
assessed in this study included age (in 5-year categories),
marital status (single, married, or widowed=divorced=
separated), education (high school and post-high school, ju-
nior college, full college, and graduate school), and study site.
All these were included in the final models, as their inclusion
resulted in a 10% or greater change between the crude and
adjusted estimates for the exposure-outcome association
when comparing the crude and adjusted associations.21 Fur-
thermore, these potential confounders may directly influence
the decision of the women in regard to compliance. The Bre-
slow-Day test for homogeneity was used to determine if the
association between DES exposure and screening behaviors
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differed by BBD and a family history of cancer. A two-sided p
value of 0.25 was considered evidence of effect measure-
modification.20
The Yates two-sided p value was used to test differences in
the screening frequency between exposed and unexposed
women. Unconditional logistic regression was used to esti-
mate the adjusted prevalence ORs for DES-exposed women
categorized by their screening frequency levels. The ordinal
variable that described their screening frequency was in-
cluded in the logistic regression models to assess whether DES
exposure was associated with a trend toward increased
screening frequency. To describe this trend, the Wald two-
sided p value test was presented.22
Results
Descriptive findings
Response rates for the 1994 questionnaire were high for all
centers: 96% of the exposed and 98% of the unexposed women
at the Boston Center, 96% of both exposed and unexposed
women at the Rochester Center, 84% of the exposed and 91%
of the unexposed at the California Center, and 89% of the
exposed and 83% of the unexposed women at the Houston
Center.
The total number of study participants who responded to
the 1994 questionnaire included 3140 exposed women and
826 unexposed women, 98% of whom were Caucasian. The
remainding 2% consisted of blacks, Hispanics, Asian or Pa-
cific islanders, and others. Among the exposed women
who responded to the 1994 questionnaire, 46% were origin-
ally recruited into the cohort through record review, 33% were
recruited through physician referral, and 21% were walk-ins.
In the unexposed population, 75% were recruited through
record review, and 25% were siblings of exposed women.
Multivariate analysis
DES-exposed women were similar to unexposed women
on study variables with the following exceptions (Table 1):
unexposed women were older (unexposed mean age¼ 42,
and DES-exposed mean age¼ 40; Yates two-sided p< 0.0001),
and DES-exposed women were more highly educated
( p< 0.0001) than unexposed women (those whose education
did not exceed high school, including nongraduates, and
those with post-high school vocational training were com-
pared with those with the higher levels of junior college
through graduate school). There was no significant difference
between exposed and unexposed women regarding marital
status ( p¼ 0.98); however, a difference was detected between
urban and rural locations (Boston, California, and Houston
were combined and compared with Mayo) ( p¼ 0.02). Fur-
thermore, the chi-square and Yates two-sided p value for BBD
and family history of cancer were found to be nonsignificant
(chi-square¼ 0.01, p¼ 0.936; chi-square¼ 0.47, p¼ 0.495, re-
spectively). The Breslow-Day test for homogeneity resulted in
a p value of 0.116 for compliant BSEs and DES exposure. There
was no effect modification found for family history of cancer.
DES-exposed and unexposed women had similar fre-
quencies of BSEs in the past 5 years [aOR (adjusted OR) 1.04,
95% CI (confidence interval) 0.87-1.25] (data not shown). This
finding held if there was a history of BBD (aOR 1.29, 95% CI
0.92-1.82) or no such history (aOR 0.96, 95% CI 0.78-1.19).
Among both exposed and unexposed women, the proportion
of women performing monthly BSEs (27% and 26%, respec-
tively) and BSEs every 2–3 months (30% and 29%, respec-
tively) was very low.
DES-exposed women <age 40 had similar reported fre-
quencies of CBE compared with unexposed women (aOR
1.17, 95% CI 0.59-2.32) (data not shown). This finding held
whether the women were defined as compliant or exceeding
recommendations, or whether or not they had a previous
history of BBD. When the adjusted analysis was further
stratified on a history of BBD, the aOR was 2.04; however, the
CI was extremely wide (95% CI 0.24-17.38, n¼ 11). There was
no difference found between the two exposure groups in the
unadjusted OR analysis.
When restricting the analysis to women who were at greater
risk of breast cancer based solely on age (40–49), DES-exposed
women relative to the unexposed women were moderately
more likely to report more than five CBEs in the past 5 years
(aOR 1.67, 95% CI 0.95-2.96) (Table 2). Among women without
BBD, however, those who were DES-exposed appeared to
have more than five CBEs in the past 5 years (aOR 2.20, 95% CI
Table 1. Demographic Characteristics and Benign
Breast Disease History in DES-Exposed
and Unexposed Women
DES exposed
(n¼ 3,140)
DES unexposed
(n¼ 826)
Characteristic n % n %
Age, years
25–29 50 2 0 0
30–34 354 11 30 4
35–39 877 28 263 32
40–44 1296 41 301 36
45–49 533 17 200 24
50–55 30 1 32 4
Education
Less than high school
and post-high school
402 13 152 18
Junior college 724 23 197 24
4-year college 1125 36 257 31
Graduate school 880 28 217 26
Missing 9 0.3 3 0.4
Marital status
Single 410 13 113 14
Married 2261 72 591 72
Widowed=divorced=
separated
425 14 105 13
Missing 44 1 17 2
Site
Boston 921 29 321 39
Rochester 588 19 186 23
Los Angeles 803 26 172 21
Houston 828 26 147 18
History of benign breast disease
Yes 777 25 207 25
No 2350 75 619 75
Missing 13 0.4 0 0
History of family cancera
Yes 1265 40 344 42
No 1831 58 470 57
Missing 44 1 12 2
aThe term family encompasses parents, siblings, and children.
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1.04-4.67) compared with DES-unexposed women, although
DES exposure was not associated with a trend toward in-
creasing CBE frequency ( p value for trend¼ 0.36).
DES-exposed and unexposed women aged 40–49 were si-
milar in compliance (two or three times in the past 5 years)
with mammography screening (45% vs. 44%) (aOR 1.03, 95%
CI 0.68-1.55) (data not shown). A similar pattern of compliance
was found in women with and without a history of BBD.
Among women who reported a history of BBD, 41% were
compliant compared with 36% of the unexposed (aOR 1.53,
95% CI 0.65-3.60). Of the women who reported no history of
BBD, 48% of the exposed women were compliant compared
with 49% in the unexposed group (aOR 1.00, 95% CI 0.62-1.63).
The analysis was repeated, but this time the women who
never had a screening examination within the past 5 years
were removed from the noncompliant group. The second
analysis was performed to test the assumption that these
women may be fundamentally different from those who have
had at least one screening examination. The results from the
secondary analysis were no different from the first; therefore,
it can be concluded that there is no statistical difference be-
tween the semicompliant behavior (at least one screening
examination in the past 5 years) and the noncompliant be-
havior (no screening examinations in the past 5 years).
Discussion
The results of this study showed that DES-exposed women
(aged 40–49) were not consistently more likely than un-
exposed women to be in compliance with recommended
Table 2. Adjusted Odds Ratios and 95% Confidence Intervals for Clinical Breast Examinations (CBEs) in Past
5 Years (1990–1994) in DES-Exposed and Unexposed Women Aged 40–49
DES exposed (n¼ 563) DES unexposed (n¼ 232)
n % n % Adjusted ORa,b 95% CIa p for trendc
Number of CBEs in past 5 yearsd
Missinge 4 0.7 2 0.9
None 18 3 8 3
Once 46 8 22 10
2–3 timesf 149 27 60 26 1.00 Referent
4–5 timesg 255 45 116 50 0.97 0.68–1.37
>5 timesh 91 16 24 10 1.67 0.95–2.96 0.39
Reported history of BBDa (n¼ 252)
DES exposed (n¼ 173) DES unexposed (n¼ 79)
n % n % Adjusted ORa,b 95% CIa p for trendc
Number of CBEs in past 5 yearsd
None 1 0.6 2 3
Once 11 6 6 8
2–3 timesf 37 21 15 19 1.00 Referent
4–5 timesg 86 50 45 57 0.87 0.44–1.70
>5 timesh 38 22 11 14 0.83 0.29–2.35 0.52
Reported No history of BBDa (n¼ 533)
DES exposed (n¼ 382) DES unexposed (n¼ 151)
n % n % Adjusted ORa,b 95% CIa p for trendc
Number of CBEs in past 5 yearsd
None 17 5 6 4
Once 35 9 16 11
2–3 timesf 110 29 45 30 1.00 Referent
4–5 timesg 168 44 71 47 1.08 0.70–1.65
>5 timesh 52 14 13 9 2.20 1.04–4.67 0.36
aOR, odds ratio; CI, confidence interval; BBD, benign breast disease.
bAdjusted for age (continuous variable), education, marital status, and site.
cThe p value (two-sided) for trend included all five outcome frequency categories; none of the frequency categories were combined for the
trend test.
dFive years [(1994–birth year)  5] were subtracted from the current questionnaire age to put the women’s respective screening age in the
proper context of the previous 5 years: no women >age 50 were present in the dataset, and only 20% were aged 40–49.
eMissing values indicate a nonresponse to the question regarding number of CBEs in the past 5 years.
fCategories (none, once, and 2–3 times) were combined to form the reference category.
gThe category 4–5 times was compared to the reference group and defined as compliant for CBE screening for this age group.
hThe category >5 times was compared to the reference group and defined as exceeding recommendations for CBE screening for this age
group.
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screening for BSE or for mammography screening. Among
women without a history of BBD, however, DES-exposed
women report more CBEs (done by a healthcare provider)
than do unexposed women. A possible explanation for this
finding may involve compliance with the women’s health
examination, where in addition to cervical screening, breast
cancer screening is performed by a clinician. Recently, DES-
exposed women were found to be overly compliant when it
came to Pap smear examinations and general physical ex-
aminations, which could explain the overcompliance for CBEs
in this study.23 The compliance for CBEs could be driven by
cervical cancer screening rather than breast cancer screening.
It has been estimated that for the years 1987–1992, 48.3% of
women reported receiving a CBE, but only 38.2% were found
through chart review, and 49.0% of women reported having a
mammogram, but only 42.4% were verified in medical re-
cords.24 In comparison with this analysis group aged 40–49,
45% of the DES-exposed group and 50% of the unexposed
reported being compliant with CBE recommendations. In the
same age group, 45% of the exposed and 44% of the un-
exposed reported having a mammogram during the re-
commended time. The results found in our study are very
similar to the results published in 1994.
A major strength of this study is that breast cancer
screenings in the DES-exposed population have not been fully
examined previously. A strength of the DESAD study was its
efforts to address the problem of selection bias. To reduce
selection bias that may result when study respondents dis-
proportionately include volunteers compared with a more
random population-based sample, medical records were
linked with live birth data for exposed and unexposed
women. Exposed women were then invited to participate in
the study.4 This strategy should have minimized selection
bias, which can occur when more health-conscience volun-
teers participate in the study, resulting in an OR moving away
from the null. Another strength of the DESAD study was its
efforts to reduce loss to follow-up. All study sites had an in-
terview response rate of at least 80% from the study inception,
and some cohorts exceeded a 90% response rate, which is rare
in any large study continuing over decades, especially when
the controls are presumed normal and have no personal rea-
son to continue in the study.
Study limitations included the potential for misclassifica-
tion of the reported frequencies of cervical and breast cancer
screenings and physical examinations. Although the DESAD
study had an established diagnosis verification system, in the
data used for this analysis, screening examinations and health
conditions were not verified by pathologic study or medical
reports. Therefore, this study relied solely on self-report of
screening and prior health conditions that were examined as
potential effect measure modifiers. This study may also have a
possible selection bias in regard to screening frequency, as
25% of the unexposed were siblings of exposed women who
may be more aware of cancer risk in general. This bias would
result in an OR toward the null, although there was no sig-
nificant difference between the exposed and unexposed
groups in regard to family cancer history.
According to previous reports, women tend to over-report
the frequency of breast cancer screening.24,25 There is no evi-
dence to suggest that DES-exposed women were more likely
than unexposed women to overreport the frequency of
screening examinations, although previous data showed that
DES-exposed women were more likely than unexposed
women to misreport their diagnoses.7 If DES-exposed women
overstated their screening frequency to a greater extent than
unexposed women, the resulting OR would be biased away
from the null value. If such a differential misclassification
were the case, however, we would expect to observe positive
associations for all screening examinations, but this did not
occur. Further, for some of the examinations, the analysis
shows similar screening frequencies among high-risk women
regardless of DES exposure status, which is further evidence
against a tendency for overreporting among exposed women.
Stratifying on a previous diagnosis of BBD led to small
numbers for all screening examinations, which possibly
weakened the power to detect a significant difference. There
was a somewhat increased risk found for CBEs in women
>age 40. The aim of the study was to determine compliance
based on the women’s perception of breast cancer risk. If the
women had a previous diagnosis of BBD, their screening be-
havior might be influenced by this and, therefore, affect their
number of breast cancer screening visits. Furthermore, as the
self-reported questionnaire data do not report how partici-
pants were recruited, we were unable to remove siblings re-
cruited through DES-exposed daughters, whose sisters’
cancer experience may affect their own screening behaviors. It
is worth noting that there were few demographic differences
between the exposed and unexposed women (Table 1).
The lack of insurance information in this study may cause
confounding by healthcare access. If DES-exposed women
were more likely than unexposed women to have insurance
and, therefore, receive more frequent screening, insurance
status, rather than DES exposure, would be the factor that led
to more frequent screening. Potential confounding could only
be operating if insurance status led to more frequent screening
and was more common in DES-exposed women. We at-
tempted to address this issue of potential confounding by
adjusting for education and marital status, which are highly
correlated with receiving preventive care26,27 and being in-
sured.28
Several papers with different conclusions discussed the
importance of BSE as reviewed by Thomas et al.,29 who did
not find a reduction in mortality rates for breast cancer by BSE
despite the intensive instruction given to participants in the
procedure. No study, to our knowledge, has shown that ex-
cessive compliance to BSE (or any other breast prevention
examination) increases detection for breast cancer; never-
theless, BSE remains a simple, cost-free procedure that may
detect palpable abnormalities in the breast, leading to early
professional consultation.
Conclusion
DES-exposed women were not different from unexposed
women when reporting breast screening examinations, except
when reporting receiving CBEs in women >age 39. Although
the majority of women in the study were not yet of age for
recommended mammography, these data suggest the DES-
exposed women (73%) are keeping the recommendation for
mammography screening and CBEs (61%), yet the majority
failed to perform monthly BSE, with 73% not meeting the
recommendation. The majority of this cohort today would be
in their mid-50s to late 50s, putting them at increased risk for
breast cancer.
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Possible suggestions for improving all screening practices
could include mailed reminders to schedule a wellness ex-
amination (when a CBE is typically performed) and a mam-
mogram. Even though BSE have not been shown to reduce
breast cancer mortality, patient consultation could include
reminders to note any changes to the breast and to contact a
provider if necessary. As this population ages, risks become
higher, and prevention using the tools provided hopefully
will improve detection or prevent advanced disease. Access to
health insurance and access to general health information
could be factors in lower compliance in preventive examina-
tions. This DES-exposed population of women will require
future efforts to notify them of their increased risk and remind
them of the importance of preventive examinations.
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